FDA commissioner Marty Makary told FDA staff in an email that Prasad, “brings a great set of skills, energy, and competence ...

This is the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and ...

The question on many minds among FDA rank-and-file in attendance was: Which Prasad would show up? The 2010s Prasad -- a ...

The UCSF professor and frequent YouTube poster has criticized COVID-19 vaccine mandates as well as the accelerated approval ...

Vinay Prasad, named to lead the FDA agency tasked with regulating vaccines and gene therapy, has made controversial comments ...

Needham lowered the firm’s price target on Sarepta (SRPT) to $125 from $183 and keeps a Buy rating on the shares. The company ...

Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...

CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...

WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

The US Food and Drug Administration has chosen Dr Vinay Prasad, a professor at the University of California-San Francisco, to lead its Center for Biologics Evaluation and Research.

In his new role with the FDA, Dr. Vinay Prasad will oversee the regulation of costly drugs, including vaccines, gene ...